Sema Akıncı

Sema Akıncı

Auto-generated profile, based on publicly available information

Sema Akıncı

Department of Hematology, Ministry of Health Ankara City Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
VOVedia Ozturk
Vedia Ozturk
AYAysun Senturk Yikilmaz
Aysun Senturk Yikilmaz
AKAydan Kilicarslan
Aydan Kilicarslan
SBSule Mine Bakanay
Sule Mine Bakanay
SASema Akinci
Sema Akinci
IDİmDat Dilek
İmDat Dilek

1 January 2015 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
TGTekin Güney
Tekin Güney
MAMurat Alisik
Murat Alisik
SASema Akinci
Sema Akinci
SNsalim neselioglu
salim neselioglu
IDİmdat Di̇lek
İmdat Di̇lek
ÖEÖzcan EREL
Özcan EREL
The aim of this study was to examine the theory that oxidative stress might have an important mediating effect on the deleterious results of vitamin B12 metabolism deficiency seen throughout the body. Forty patients with vitamin B12 deficiency and 40 healthy controls were included in the study. Venous blood samples were collected from all participants to evaluate serum vitamin B12, homocysteine, methylmalonic acid, total antioxidant status (TAS), and total oxidant status (TOS) levels in the pre- and posttreatment periods. There were no significant differences in TAS, TOS, or oxidative stress index (OSI) levels between the pretreatment patient and control groups, and there were no significant differences in TAS or TOS levels between the posttreatment and control groups. In addition, there were no significant differences between the pre- and posttreatment TAS, TOS, and OSI levels of the patients. These findings are remarkable in that cyanocobalamin treatment had no direct effect on oxidant and antioxidant status in patients with vitamin B12 deficiency. The fact that there were no differences in oxidant and antioxidant status between the patients and the controls might suggest that oxidative stress does not play a role in the systemic negative effects of vitamin B12 deficiency.

22 January 2015 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
SASema Akinci
Sema Akinci
KSKamile Silay
Kamile Silay
AUArife Ulas
Arife Ulas
TGTekin Guney
Tekin Guney
THTuba Hacibekiroglu
Tuba Hacibekiroglu
IDImdat Dilek
Imdat Dilek
Neutrophil to Lymphocyte Ratio - Not an Independent Prognostic Factor in Patients with the Myelodysplastic Syndrome Myelodysplastic syndrome;neutrophil/lymphocyte ratio;cytopenia;prognosis; Purpose: Neutrophil-to-lymphocyte ratio (NLR) was evaluated as a potential prognostic factor in patients with myelodysplastic syndrome (MDS). Materials and Methods: Between December 2009 and April 2014, 14 female (35%) and 26 male (65%) MDS patients who were followed up in our hematology clinic were included in the study for NLR during diagnosis. Division was into two groups according to the NLR, and the correlation with mortality was evaluated. The prognostic significance of NLR regarding treatment outcome was also evaluated with adjustment for known confounding risk factors. Results: The mortality rate of the patient group was 55%, and median survival was 18 months. There was no significant correlation between mortality and NLR at a median value of 1.8 (p=0.75). Thrombocytopenia was observed to increase mortality (p=0.027), and there was a significant correlation between mortality and pancytopenia (p=0.017). Conclusions: This first study of NLR and mortality did not show any significant correlation. In centres with limited access to genetic evaluation for the presence of pancytopenia and/or thrombocytopenia at the time of diagnosis, a platelet level less than $50{\times}10^9/l$ may be poor prognostic markers in MDS patients.

24 February 2022 in Turkish Journal of Hematology
Verified
Journal Article
Open access
TGTekin Güney
Tekin Güney
FCFerda Can
Ferda Can
SASema Akıncı
Sema Akıncı
ÖKÖzge Soyer Kösemehmetoğlu
Özge Soyer Kösemehmetoğlu
IDİmdat Dilek
İmdat Dilek

1 January 2016 in European Journal of Health Sciences
Verified
Journal Article
Closed access
ABAbdulkadir Basturk
Abdulkadir Basturk
LKLeyla Kutlucan
Leyla Kutlucan
AKAli Kutlucan
Ali Kutlucan
APAybüke Tazegül Pekin
Aybüke Tazegül Pekin
SASema Akıncı
Sema Akıncı
SDSüleyman Dinçer
Süleyman Dinçer

1 October 2021 in Clinical Hemorheology and Microcirculation
Verified
Journal Article
Closed access
PDF file
TGTekin Güney
Tekin Güney
FCFerda Can
Ferda Can
AAAfra Alkan
Afra Alkan
SASema Akıncı
Sema Akıncı
IDİmDat Dilek
İmDat Dilek
INTRODUCTION: Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by thrombocytosis with megakaryocytic hyperplasia where in the thrombocytes are increased with abnormal function. Thrombotic events are seen frequently and represent the main cause of morbidity and mortality in patients with MPNs, mainly polycythemia vera and ET. This study has aimed to research the effects of clonally increased thrombocytes on plasma viscosity (PV) levels among patients with ET and the relationship between PV and thromboembolism history, according to the hypotheses about the effects of PV in thromboembolic events among patients with ET. METHODS: A total of 55 patients were enrolled in the study group, 18 of who had been newly diagnosed with ET according to 2016 World Health Organization criteria and had not previously been treated. 37 of them had already been diagnosed with ET and had been treated. There were 47 healthy volunteers in the control group. 5 cc blood samples were taken from the patients into tubes including an anticoagulant to measure their PV levels. RESULTS: PV of the control group was found to be lower than in the study group and both each patient groups ( p < 0.05). No relationship was found between the patient groups in terms of PV ( p = 0.404). The mean PV levels of the 16 patients with a history of thromboembolism and the 39 patients with no such history were 2.42±0.17 cP and 2.33±0.20 cP, respectively. The mean PV levels were found to be similar according to their history of thromboembolism in all patient groups and in treated patients ( p = 0.572 vs p = 0.991). CONCLUSION: We have found that PV levels were increased in clonally increased thrombocytes in patients with ET when compared with the control group. This is the first study in this field according to our knowledge.